Home › Companies › LIFECORE BIOMEDICAL INC. › 2024-2025

LIFECORE BIOMEDICAL INC. 2024-2025 Proxy Voting Records

Compiled from SEC Form N-PX filings and LIFECORE BIOMEDICAL INC.’s Form 8-K, filed 2024-11-08 (Item 5.07 on EDGAR). Page generated 02 October 2026.

18Reported items
105Asset managers
1,070Fund votes
2024-11-07Main meeting date

Proxy season: 2024-2025 2025-2026

Explore LIFECORE BIOMEDICAL INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by LIFECORE BIOMEDICAL INC.

These tallies are LIFECORE BIOMEDICAL INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2024-11-08 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX. LIFECORE BIOMEDICAL INC. reported 2 meetings in this season; each is tabulated separately below, with its own filing.

LIFECORE BIOMEDICAL INC. — official shareholder meeting results, meeting held 2024-11-07 (Form 8-K, filed 2024-11-08)
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Matthew Korenberg	23,645,673	191,321	--	12,392	7,498,295	Majority: yes
Elect Director: Humberto Antunes	23,712,493	124,501	--	12,392	7,498,295	Majority: yes
Elect Director: Nelson Obus	21,721,070	2,115,224	--	13,092	7,498,295	Majority: yes
Elect Director: Katrina Houde	20,973,514	2,827,981	--	47,891	7,498,295	Majority: yes
As a result of the foregoing voting results, each of the foregoing directors was appointed to the Board of Directors of the Company to serve for a term expiring at the 2025 Annual Meeting and until their successors are duly elected and qual	31,279,291	29,609	38,781	--	--	Majority: yes
Proposal 3: Stockholders approved the compensation paid to the Company's named executive officers (in the form of a non-binding, advisory vote), with votes as follows:	23,645,284	163,003	41,099	--	7,498,295	Majority: yes

Source: LIFECORE BIOMEDICAL INC., Form 8-K, filed with the SEC on 2024-11-08 — read the filing on EDGAR.

LIFECORE BIOMEDICAL INC. — official shareholder meeting results, meeting held 2025-04-10 (Form 8-K, filed 2025-04-10)
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Proposal 2: Stockholders approved the Adjournment Proposal, with votes as follows.	28,882,501	464,086	35,505	--	--	Majority: yes

Source: LIFECORE BIOMEDICAL INC., Form 8-K, filed with the SEC on 2025-04-10 — read the filing on EDGAR.

How asset managers voted at the LIFECORE BIOMEDICAL INC. 2024-2025 meetings

Each item below shows how the 105 asset managers that disclosed a LIFECORE BIOMEDICAL INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of LIFECORE BIOMEDICAL INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To approve a non-binding advisory proposal on the compensation of the Company's named executive officers, as described in the Proxy Statement.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Meeting held 2024-11-07.

Combines 8 wordings of this item as funds reported it.

99.3% Majority: yes · of votes cast

FOR 99.3%

FOR: 23,645,284AGAINST: 163,003

LIFECORE BIOMEDICAL INC.’s own tally for this item (“Proposal 3: Stockholders approved the compensation paid to the Company's named executive officers (in the form of a non-binding, advisory vote), with votes as follows:”): 23,645,284 for, 163,003 against, per its Form 8-K filed 2024-11-08 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 30,898,255 outstanding shares: 77% for, 0.6% against (77% of the company cast a for/against vote).

The 85 asset managers below cast 98% of the shares they voted on this item FOR (18,628,631 for, 313,506 against).

FOR 98%

FOR: 18,628,631 (98.3%)AGAINST: 313,506 (1.7%)

Largest asset managers voting on “To approve a non-binding advisory proposal on the compensation of the Company's named executive officers, as d” at LIFECORE BIOMEDICAL INC., 2024-2025
Asset manager	For	Against	Vote
Legion Partners Asset Management, LLC	4,403,754	0	For
Greenhaven Road Investment Management, L.P.	3,616,146	0	For
WYNNEFIELD CAPITAL INC	3,483,137	0	For
22NW, LP	1,771,697	0	For
325 CAPITAL LLC	1,369,785	0	For
Vanguard	1,317,318	0	For
BlackRock	736,540	0	For
State Street	300,080	0	For
DCF Advisers, LLC	0	288,478	Against
Rangeley Capital, LLC	211,799	0	For
GEODE CAPITAL MANAGEMENT, LLC	154,451	0	For
TOCQUEVILLE ASSET MANAGEMENT L.P.	151,700	0	For
Fidelity	148,291	0	For
Northern Trust	136,421	0	For
Charles Schwab	110,583	0	For
PARAMETRIC PORTFOLIO ASSOCIATES LLC	92,106	0	For
MELLON INVESTMENTS Corp	66,261	0	For
WITTENBERG INVESTMENT MANAGEMENT, INC.	57,896	0	For
BRIDGEWAY CAPITAL MANAGEMENT, LLC	55,700	0	For
BRIDGEWAY FUNDS INC	55,700	0	For
QUANTITATIVE MASTER SERIES LLC	42,480	0	For
Gabelli	37,400	0	For
American Century	28,752	0	For
Equitable	27,170	0	For
Nuveen	26,237	0	For

Showing the 25 largest of 85 asset managers. See all 85 in the interactive database.

2. TO APPROVE A NON-BINDING ADVISORY PROPOSAL ON THE EXECUTIVE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS, AS DESCRIBED IN THE PROXY STATEMENT.

SECTION 14A SAY-ON-PAY VOTES

Meeting held 2024-08-15; no official results are on file for this meeting.

Combines 3 wordings of this item as funds reported it.

99.9% fund support · no official result

FOR 73%FOR - 1 YEAR 27%

The 52 asset managers below cast 99.9% of the shares they voted on this item FOR (8,036,150 for, 28 against).

FOR: 8,036,150 (73.2%)AGAINST: 28 (0.0%)FOR - 1 YEAR: 2,940,340 (26.8%)

Largest asset managers voting on “TO APPROVE A NON-BINDING ADVISORY PROPOSAL ON THE EXECUTIVE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFI” at LIFECORE BIOMEDICAL INC., 2024-2025
Asset manager	For	Vote
WYNNEFIELD CAPITAL INC	4,165,822	For
Legion Partners Asset Management, LLC	0	For - 1 Year
325 CAPITAL LLC	1,340,598	For
Vanguard	1,187,762	For
BlackRock	301,836	For
TOCQUEVILLE ASSET MANAGEMENT L.P.	151,700	For
State Street	120,796	For
PARAMETRIC PORTFOLIO ASSOCIATES LLC	105,386	For
MARSHALL WACE, LLP	101,421	For
American Century	86,814	For
GEODE CAPITAL MANAGEMENT, LLC	69,868	For
Gabelli	67,505	For
Fidelity	65,031	For
Diversified Trust Co	46,062	For
Equitable	44,193	For
Northern Trust	36,355	For
BALYASNY ASSET MANAGEMENT L.P.	22,674	For
Charles Schwab	20,854	For
BRIDGEWAY CAPITAL MANAGEMENT, LLC	16,116	For
BRIDGEWAY FUNDS INC	16,116	For
Citadel	13,958	For
Laurion Capital Management LP	11,112	For
Sterling Capital Management LLC	10,000	For
Victory Capital	7,642	For
Crestwood Advisors Group, LLC	6,890	For

Showing the 25 largest of 52 asset managers. See all 52 in the interactive database.

3. TO APPROVE A NON-BINDING ADVISORY PROPOSAL ON THE FREQUENCY OF FUTURE ADVISORY VOTES TO APPROVE THE COMPANY'S NAMED EXECUTIVE OFFICER COMPENSATION.

SECTION 14A SAY-ON-PAY VOTES

Meeting held 2024-08-15; no official results are on file for this meeting.

Combines 2 wordings of this item as funds reported it.

— fund support · no official result

ONE YEAR 84%1 YEAR 16%

No shares were cast for or against this item by the managers below — every disclosed position was an abstention or was not voted.

ONE YEAR: 3,247,707 (83.9%)1 YEAR: 622,640 (16.1%)

Largest asset managers voting on “TO APPROVE A NON-BINDING ADVISORY PROPOSAL ON THE FREQUENCY OF FUTURE ADVISORY VOTES TO APPROVE THE COMPANY'S ” at LIFECORE BIOMEDICAL INC., 2024-2025
Asset manager	For	Against	Abstain	Withheld	Vote
325 CAPITAL LLC	0	0	0	0	One Year
Vanguard	0	0	0	0	One Year
BlackRock	0	0	0	0	1 Year
TOCQUEVILLE ASSET MANAGEMENT L.P.	0	0	0	0	One Year
State Street	0	0	0	0	One Year
PARAMETRIC PORTFOLIO ASSOCIATES LLC	0	0	0	0	One Year
MARSHALL WACE, LLP	0	0	0	0	1 Year
American Century	0	0	0	0	One Year
GEODE CAPITAL MANAGEMENT, LLC	0	0	0	0	One Year
Gabelli	0	0	0	0	1 Year
Fidelity	0	0	0	0	One Year
Diversified Trust Co	0	0	0	0	1 Year
Equitable	0	0	0	0	One Year
Northern Trust	0	0	0	0	1 Year
BALYASNY ASSET MANAGEMENT L.P.	0	0	0	0	1 Year
Charles Schwab	0	0	0	0	1 Year
BRIDGEWAY CAPITAL MANAGEMENT, LLC	0	0	0	0	One Year
BRIDGEWAY FUNDS INC	0	0	0	0	One Year
Citadel	0	0	0	0	One Year
Laurion Capital Management LP	0	0	0	0	One Year
Sterling Capital Management LLC	0	0	0	0	1 Year
Victory Capital	0	0	0	0	One Year
Crestwood Advisors Group, LLC	0	0	0	0	1 Year
HM PAYSON & CO	0	0	0	0	1 Year
Nierenberg Investment Management Company, Inc.	0	0	0	0	1 Year

Showing the 25 largest of 50 asset managers. See all 50 in the interactive database.

4. TO APPROVE AN ADJOURNMENT OF THE SPECIAL MEETING, IF NECESSARY OR APPROPRIATE, TO SOLICIT ADDITIONAL PROXIES IF THERE ARE NOT SUFFICIENT VOTES IN FAVOR OF THE ISSUANCE PROPOSAL.

CORPORATE GOVERNANCEMajority of the votes cast: yes

Meeting held 2025-04-10.

98% Majority: yes · of votes cast

FOR 98%

FOR: 28,882,501AGAINST: 464,086

LIFECORE BIOMEDICAL INC.’s own tally for this item (“Proposal 2: Stockholders approved the Adjournment Proposal, with votes as follows.”): 28,882,501 for, 464,086 against, per its Form 8-K filed 2025-04-10 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 30,898,255 outstanding shares: 93% for, 2% against (95% of the company cast a for/against vote).

The 33 asset managers below cast 99.2% of the shares they voted on this item FOR (3,030,260 for, 21,840 against).

FOR 99.2%

FOR: 3,030,260 (99.3%)AGAINST: 21,840 (0.7%)

Largest asset managers voting on “TO APPROVE AN ADJOURNMENT OF THE SPECIAL MEETING, IF NECESSARY OR APPROPRIATE, TO SOLICIT ADDITIONAL PROXIES I” at LIFECORE BIOMEDICAL INC., 2024-2025
Asset manager	For	Against	Vote
Vanguard	1,503,843	0	For
BlackRock	625,781	0	For
Fidelity	521,469	0	For
Equitable	90,430	0	For
Charles Schwab	74,427	0	For
QUANTITATIVE MASTER SERIES LLC	36,236	0	For
RBC FUNDS TRUST	29,300	0	For
WisdomTree	26,569	0	For
Lincoln Financial	0	17,000	Against
Gabelli	13,500	0	For
Northern Trust	13,478	0	For
Global X	12,829	0	For
BRIDGEWAY FUNDS INC	12,564	0	For
Bridge Builder Trust	11,817	0	For
Pacific Life	11,349	0	For
John Hancock	9,255	0	For
Voya	7,440	0	For
ProShares	5,716	0	For
AIG/SunAmerica	4,696	0	For
Goldman Sachs	3,980	0	For
Victory Capital	3,837	0	For
Nationwide	3,751	0	For
DWS	3,517	0	For
T. Rowe Price	0	2,122	Against
Calvert	2,087	0	For

Showing the 25 largest of 33 asset managers. See all 33 in the interactive database.

5. To elect four non-Series A Preferred Director, as described in the Proxy Statement, for a term expiring at the 2025 annual meeting stockholders and until their successors are duly elected and qualified: Humberto Antunes

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2024-11-07.

Combines 4 wordings of this item as funds reported it.

99.4% Majority: yes · of votes cast

FOR 99.4%

FOR: 23,712,493AGAINST: 124,501

LIFECORE BIOMEDICAL INC.’s own tally for this item (“Elect Director: Humberto Antunes”): 23,712,493 for, 124,501 against, per its Form 8-K filed 2024-11-08 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 30,898,255 outstanding shares: 77% for, 0.5% against (77% of the company cast a for/against vote).

The 32 asset managers below cast 100% of the shares they voted on this item FOR (2,029,069 for, 0 against).

FOR 100%

FOR: 2,029,069 (100.0%)

Largest asset managers voting on “To elect four non-Series A Preferred Director, as described in the Proxy Statement, for a term expiring at the” at LIFECORE BIOMEDICAL INC., 2024-2025
Asset manager	For	Vote
Vanguard	1,293,361	For
BlackRock	229,840	For
Fidelity	146,786	For
Charles Schwab	60,505	For
BRIDGEWAY FUNDS INC	55,700	For
QUANTITATIVE MASTER SERIES LLC	42,480	For
Equitable	27,170	For
TIAA	26,237	For
Lincoln Financial	17,000	For
Gabelli	16,200	For
American Century	14,376	For
Northern Trust	13,478	For
AIG/SunAmerica	12,077	For
Global X	11,690	For
Pacific Life	9,102	For
Bridge Builder Trust	9,061	For
Voya	8,363	For
GuideStone	8,221	For
Columbia Threadneedle	6,063	For
ProShares	4,748	For
Victory Capital	3,606	For
DWS	3,380	For
Calvert	2,087	For
T. Rowe Price	1,566	For
State Street	1,552	For

Showing the 25 largest of 32 asset managers. See all 32 in the interactive database.

6. To elect four non-Series A Preferred Director, as described in the Proxy Statement, for a term expiring at the 2025 annual meeting stockholders and until their successors are duly elected and qualified: Katrina L. Houde

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2024-11-07.

Combines 4 wordings of this item as funds reported it.

88% Majority: yes · of votes cast

FOR 88%12%

FOR: 20,973,514AGAINST: 2,827,981

LIFECORE BIOMEDICAL INC.’s own tally for this item (“Elect Director: Katrina Houde”): 20,973,514 for, 2,827,981 against, per its Form 8-K filed 2024-11-08 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 30,898,255 outstanding shares: 68% for, 9% against (77% of the company cast a for/against vote).

The 32 asset managers below cast 73% of the shares they voted on this item FOR (1,471,658 for, 557,411 against).

FOR 73%AGAINST 27%

FOR: 1,471,658 (72.5%)AGAINST: 557,411 (27.5%)

Largest asset managers voting on “To elect four non-Series A Preferred Director, as described in the Proxy Statement, for a term expiring at the” at LIFECORE BIOMEDICAL INC., 2024-2025
Asset manager	For	Against	Vote
Vanguard	1,293,361	0	For
BlackRock	0	229,840	Against
Fidelity	146,786	0	For
Charles Schwab	0	60,505	Against
BRIDGEWAY FUNDS INC	0	55,700	Against
QUANTITATIVE MASTER SERIES LLC	0	42,480	Against
Equitable	15,200	11,970	For
TIAA	0	26,237	Against
Lincoln Financial	0	17,000	Against
Gabelli	16,200	0	For
American Century	0	14,376	Against
Northern Trust	0	13,478	Against
AIG/SunAmerica	0	12,077	Against
Global X	0	11,690	Against
Pacific Life	0	9,102	Against
Bridge Builder Trust	0	9,061	Against
Voya	0	8,363	Against
GuideStone	0	8,221	Against
Columbia Threadneedle	0	6,063	Against
ProShares	0	4,748	Against
Victory Capital	0	3,606	Against
DWS	0	3,380	Against
Calvert	0	2,087	Against
T. Rowe Price	0	1,566	Against
State Street	0	1,552	Against

Showing the 25 largest of 32 asset managers. See all 32 in the interactive database.

7. To elect four non-Series A Preferred Director, as described in the Proxy Statement, for a term expiring at the 2025 annual meeting stockholders and until their successors are duly elected and qualified: Matthew Korenberg

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2024-11-07.

Combines 4 wordings of this item as funds reported it.

99.1% Majority: yes · of votes cast

FOR 99.1%

FOR: 23,645,673AGAINST: 191,321

LIFECORE BIOMEDICAL INC.’s own tally for this item (“Elect Director: Matthew Korenberg”): 23,645,673 for, 191,321 against, per its Form 8-K filed 2024-11-08 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 30,898,255 outstanding shares: 77% for, 0.7% against (77% of the company cast a for/against vote).

The 32 asset managers below cast 100% of the shares they voted on this item FOR (2,029,069 for, 0 against).

FOR 100%

FOR: 2,029,069 (100.0%)

Largest asset managers voting on “To elect four non-Series A Preferred Director, as described in the Proxy Statement, for a term expiring at the” at LIFECORE BIOMEDICAL INC., 2024-2025
Asset manager	For	Vote
Vanguard	1,293,361	For
BlackRock	229,840	For
Fidelity	146,786	For
Charles Schwab	60,505	For
BRIDGEWAY FUNDS INC	55,700	For
QUANTITATIVE MASTER SERIES LLC	42,480	For
Equitable	27,170	For
TIAA	26,237	For
Lincoln Financial	17,000	For
Gabelli	16,200	For
American Century	14,376	For
Northern Trust	13,478	For
AIG/SunAmerica	12,077	For
Global X	11,690	For
Pacific Life	9,102	For
Bridge Builder Trust	9,061	For
Voya	8,363	For
GuideStone	8,221	For
Columbia Threadneedle	6,063	For
ProShares	4,748	For
Victory Capital	3,606	For
DWS	3,380	For
Calvert	2,087	For
T. Rowe Price	1,566	For
State Street	1,552	For

Showing the 25 largest of 32 asset managers. See all 32 in the interactive database.

8. To elect four non-Series A Preferred Director, as described in the Proxy Statement, for a term expiring at the 2025 annual meeting stockholders and until their successors are duly elected and qualified: Nelson Obus

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2024-11-07.

Combines 4 wordings of this item as funds reported it.

91% Majority: yes · of votes cast

FOR 91%9%

FOR: 21,721,070AGAINST: 2,115,224

LIFECORE BIOMEDICAL INC.’s own tally for this item (“Elect Director: Nelson Obus”): 21,721,070 for, 2,115,224 against, per its Form 8-K filed 2024-11-08 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 30,898,255 outstanding shares: 70% for, 7% against (77% of the company cast a for/against vote).

The 32 asset managers below cast 80% of the shares they voted on this item FOR (1,632,008 for, 397,061 against).

FOR 80%AGAINST 20%

FOR: 1,632,008 (80.4%)AGAINST: 397,061 (19.6%)

Largest asset managers voting on “To elect four non-Series A Preferred Director, as described in the Proxy Statement, for a term expiring at the” at LIFECORE BIOMEDICAL INC., 2024-2025
Asset manager	For	Against	Vote
Vanguard	1,293,361	0	For
BlackRock	0	229,840	Against
Fidelity	146,786	0	For
Charles Schwab	60,505	0	For
BRIDGEWAY FUNDS INC	0	55,700	Against
QUANTITATIVE MASTER SERIES LLC	0	42,480	Against
Equitable	19,580	7,590	For
TIAA	0	26,237	Against
Lincoln Financial	17,000	0	For
Gabelli	16,200	0	For
American Century	14,376	0	For
Northern Trust	0	13,478	Against
AIG/SunAmerica	12,077	0	For
Global X	11,690	0	For
Pacific Life	0	9,102	Against
Bridge Builder Trust	0	9,061	Against
Voya	8,363	0	For
GuideStone	8,221	0	For
Columbia Threadneedle	6,063	0	For
ProShares	4,748	0	For
Victory Capital	3,606	0	For
DWS	3,380	0	For
Calvert	0	2,087	Against
T. Rowe Price	1,566	0	For
State Street	1,552	0	For

Showing the 25 largest of 32 asset managers. See all 32 in the interactive database.

9. RATIFICATION OF THE APPOINTMENT OF BDO USA, P.C. AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING MAY 25, 2025.

AUDIT-RELATED

Meeting held 2024-11-07.

100% fund support · no official result

FOR 100%

The 31 asset managers below cast 100% of the shares they voted on this item FOR (2,020,848 for, 0 against).

FOR: 2,020,848 (100.0%)

Largest asset managers voting on “RATIFICATION OF THE APPOINTMENT OF BDO USA, P.C. AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIR” at LIFECORE BIOMEDICAL INC., 2024-2025
Asset manager	For	Vote
Vanguard	1,293,361	For
BlackRock	229,840	For
Fidelity	146,786	For
Charles Schwab	60,505	For
BRIDGEWAY FUNDS INC	55,700	For
QUANTITATIVE MASTER SERIES LLC	42,480	For
Equitable	27,170	For
TIAA	26,237	For
Lincoln Financial	17,000	For
Gabelli	16,200	For
American Century	14,376	For
Northern Trust	13,478	For
AIG/SunAmerica	12,077	For
Global X	11,690	For
Pacific Life	9,102	For
Bridge Builder Trust	9,061	For
Voya	8,363	For
Columbia Threadneedle	6,063	For
ProShares	4,748	For
Victory Capital	3,606	For
DWS	3,380	For
Calvert	2,087	For
T. Rowe Price	1,566	For
State Street	1,552	For
Morgan Stanley	1,375	For

Showing the 25 largest of 31 asset managers. See all 31 in the interactive database.

10. For purposes of complying with Nasdaq Listing Rule 5635(d), to approve the issuance of shares of our common stock ("Common Stock") underlying shares of Series A Preferred Stock, par value $0.001 per share, of the Company (the "Series A Preferred Stock") issued by the Company pursuant to the terms of that certain Securities Purchase Agreement, dated January 9, 2023, by and among the Company and the

CAPITAL STRUCTURE

Meeting held 2025-04-10.

Combines 2 wordings of this item as funds reported it.

99.1% fund support · no official result

FOR 99.1%

The 26 asset managers below cast 99.1% of the shares they voted on this item FOR (2,306,423 for, 19,718 against).

FOR: 2,306,423 (99.2%)AGAINST: 19,718 (0.8%)

Largest asset managers voting on “For purposes of complying with Nasdaq Listing Rule 5635(d), to approve the issuance of shares of our common st” at LIFECORE BIOMEDICAL INC., 2024-2025
Asset manager	For	Against	Vote
Vanguard	1,503,843	0	For
Fidelity	521,469	0	For
Equitable	90,430	0	For
Charles Schwab	74,427	0	For
WisdomTree	26,569	0	For
Lincoln Financial	0	17,000	Against
Northern Trust	13,478	0	For
Global X	12,829	0	For
BRIDGEWAY FUNDS INC	12,564	0	For
Pacific Life	11,349	0	For
Voya	7,440	0	For
ProShares	5,716	0	For
AIG/SunAmerica	4,696	0	For
Goldman Sachs	3,980	0	For
Victory Capital	3,837	0	For
Nationwide	3,751	0	For
DWS	3,517	0	For
T. Rowe Price	2,122	0	For
Calvert	2,087	0	For
Brighthouse	1,822	0	For
State Street	0	1,062	Against
PENN SERIES FUNDS INC	0	900	Against
Brinker Capital Destinations Trust	0	756	Against
TIAA	289	0	For
Guggenheim	203	0	For

Showing the 25 largest of 26 asset managers. See all 26 in the interactive database.

11. TO APPROVE AN AMENDMENT TO THE COMPANY'S 2019 STOCK INCENTIVE PLAN, INCLUDING AN INCREASE IN THE NUMBER OF SHARES AUTHORIZED FOR ISSUANCE THEREUNDER BY 300,000 SHARES OF COMMON STOCK.

COMPENSATION

Meeting held 2024-08-15; no official results are on file for this meeting.

Combines 2 wordings of this item as funds reported it.

98% fund support · no official result

FOR 98%

The 13 asset managers below cast 98% of the shares they voted on this item FOR (4,260,572 for, 105,912 against).

FOR: 4,260,572 (97.6%)AGAINST: 105,912 (2.4%)

Largest asset managers voting on “TO APPROVE AN AMENDMENT TO THE COMPANY'S 2019 STOCK INCENTIVE PLAN, INCLUDING AN INCREASE IN THE NUMBER OF SHA” at LIFECORE BIOMEDICAL INC., 2024-2025
Asset manager	For	Against	Vote
Legion Partners Asset Management, LLC	2,940,340	0	For
Vanguard	1,174,091	0	For
Fidelity	63,632	0	For
BlackRock	46,777	0	For
Equitable	988	43,205	Against
American Century	0	43,407	Against
Gabelli	0	19,300	Against
BRIDGEWAY FUNDS INC	16,116	0	For
Charles Schwab	10,427	0	For
Victory Capital	3,821	0	For
Northern Trust	3,540	0	For
John Hancock	729	0	For
Advisors' Inner Circle Fund III	111	0	For

12. To elect three non-Series A Preferred Directors, as described in the Proxy Statement, for a term expiring at the 2025 annual meeting of stockholders and until their successors are duly elected and qualified: Joshua E. Schechter

DIRECTOR ELECTIONS

Meeting held 2024-08-15; no official results are on file for this meeting.

Combines 2 wordings of this item as funds reported it.

95% fund support · no official result

FOR 95%

The 12 asset managers below cast 95% of the shares they voted on this item FOR (1,358,723 for, 67,421 against).

FOR: 1,358,723 (95.3%)AGAINST: 67,421 (4.7%)

Largest asset managers voting on “To elect three non-Series A Preferred Directors, as described in the Proxy Statement, for a term expiring at t” at LIFECORE BIOMEDICAL INC., 2024-2025
Asset manager	For	Against	Vote
Vanguard	1,174,091	0	For
Fidelity	63,632	0	For
BlackRock	0	46,777	Against
Equitable	43,205	988	For
American Century	43,407	0	For
Gabelli	19,300	0	For
BRIDGEWAY FUNDS INC	0	16,116	Against
Charles Schwab	10,427	0	For
Victory Capital	3,821	0	For
Northern Trust	0	3,540	Against
John Hancock	729	0	For
Advisors' Inner Circle Fund III	111	0	For

13. To elect three non-Series A Preferred Directors, as described in the Proxy Statement, for a term expiring at the 2025 annual meeting of stockholders and until their successors are duly elected and qualified: Paul Josephs

DIRECTOR ELECTIONS

Meeting held 2024-08-15; no official results are on file for this meeting.

Combines 2 wordings of this item as funds reported it.

100% fund support · no official result

FOR 100%

The 12 asset managers below cast 100% of the shares they voted on this item FOR (1,426,144 for, 0 against).

FOR: 1,426,144 (100.0%)

Largest asset managers voting on “To elect three non-Series A Preferred Directors, as described in the Proxy Statement, for a term expiring at t” at LIFECORE BIOMEDICAL INC., 2024-2025
Asset manager	For	Vote
Vanguard	1,174,091	For
Fidelity	63,632	For
BlackRock	46,777	For
Equitable	44,193	For
American Century	43,407	For
Gabelli	19,300	For
BRIDGEWAY FUNDS INC	16,116	For
Charles Schwab	10,427	For
Victory Capital	3,821	For
Northern Trust	3,540	For
John Hancock	729	For
Advisors' Inner Circle Fund III	111	For

14. To elect three non-Series A Preferred Directors, as described in the Proxy Statement, for a term expiring at the 2025 annual meeting of stockholders and until their successors are duly elected and qualified: Raymond Diradoorian

DIRECTOR ELECTIONS

Meeting held 2024-08-15; no official results are on file for this meeting.

Combines 2 wordings of this item as funds reported it.

98% fund support · no official result

FOR 98%

The 12 asset managers below cast 98% of the shares they voted on this item FOR (1,399,601 for, 26,543 against).

FOR: 1,399,601 (98.1%)AGAINST: 26,543 (1.9%)

Largest asset managers voting on “To elect three non-Series A Preferred Directors, as described in the Proxy Statement, for a term expiring at t” at LIFECORE BIOMEDICAL INC., 2024-2025
Asset manager	For	Against	Vote
Vanguard	1,174,091	0	For
Fidelity	63,632	0	For
BlackRock	46,777	0	For
Equitable	44,193	0	For
American Century	43,407	0	For
Gabelli	19,300	0	For
BRIDGEWAY FUNDS INC	0	16,116	Against
Charles Schwab	0	10,427	Against
Victory Capital	3,821	0	For
Northern Trust	3,540	0	For
John Hancock	729	0	For
Advisors' Inner Circle Fund III	111	0	For

15. RATIFICATION OF THE APPOINTMENT OF BDO USA, P.C. AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING MAY 26, 2024.

AUDIT-RELATED

Meeting held 2024-08-15; no official results are on file for this meeting.

100% fund support · no official result

FOR 100%

The 12 asset managers below cast 100% of the shares they voted on this item FOR (1,426,144 for, 0 against).

FOR: 1,426,144 (100.0%)

Largest asset managers voting on “RATIFICATION OF THE APPOINTMENT OF BDO USA, P.C. AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIR” at LIFECORE BIOMEDICAL INC., 2024-2025
Asset manager	For	Vote
Vanguard	1,174,091	For
Fidelity	63,632	For
BlackRock	46,777	For
Equitable	44,193	For
American Century	43,407	For
Gabelli	19,300	For
BRIDGEWAY FUNDS INC	16,116	For
Charles Schwab	10,427	For
Victory Capital	3,821	For
Northern Trust	3,540	For
John Hancock	729	For
Advisors' Inner Circle Fund III	111	For

16. TO APPROVE THE AMENDMENT OF ARTICLE VI OF THE CHARTER TO INCREASE THE NUMBER OF AUTHORIZED SHARES OF COMMON STOCK.

CAPITAL STRUCTURE

Meeting held 2024-08-15; no official results are on file for this meeting.

Combines 2 wordings of this item as funds reported it.

100% fund support · no official result

FOR 100%

The 12 asset managers below cast 100% of the shares they voted on this item FOR (1,426,144 for, 0 against).

FOR: 1,426,144 (100.0%)

Largest asset managers voting on “TO APPROVE THE AMENDMENT OF ARTICLE VI OF THE CHARTER TO INCREASE THE NUMBER OF AUTHORIZED SHARES OF COMMON ST” at LIFECORE BIOMEDICAL INC., 2024-2025
Asset manager	For	Vote
Vanguard	1,174,091	For
Fidelity	63,632	For
BlackRock	46,777	For
Equitable	44,193	For
American Century	43,407	For
Gabelli	19,300	For
BRIDGEWAY FUNDS INC	16,116	For
Charles Schwab	10,427	For
Victory Capital	3,821	For
Northern Trust	3,540	For
John Hancock	729	For
Advisors' Inner Circle Fund III	111	For

17. To approve the amendment of Article VI of the Amended and Restated Certificate of Incorporation of Lifecore Biomedical, Inc., as amended (the "Charter"), to provide for the phased in declassification of the Board of Directors.

SHAREHOLDER RIGHTS AND DEFENSES

Meeting held 2024-08-15; no official results are on file for this meeting.

Combines 2 wordings of this item as funds reported it.

100% fund support · no official result

FOR 100%

The 11 asset managers below cast 100% of the shares they voted on this item FOR (1,426,033 for, 0 against).

FOR: 1,426,033 (100.0%)

Largest asset managers voting on “To approve the amendment of Article VI of the Amended and Restated Certificate of Incorporation of Lifecore Bi” at LIFECORE BIOMEDICAL INC., 2024-2025
Asset manager	For	Vote
Vanguard	1,174,091	For
Fidelity	63,632	For
BlackRock	46,777	For
Equitable	44,193	For
American Century	43,407	For
Gabelli	19,300	For
BRIDGEWAY FUNDS INC	16,116	For
Charles Schwab	10,427	For
Victory Capital	3,821	For
Northern Trust	3,540	For
John Hancock	729	For

18. FOR PURPOSES OF COMPLYING WITH NASDAQ LISTING RULE 5635(D), TO APPROVE THE ISSUANCE OF SHARES OF OUR COMMON STOCK UNDERLYING SHARES OF SERIES A PREFERRED STOCK, PAR VALUE $0.001 PER SHARE, OF THE COMPANY ISSUED BY THE COMPANY PURSUANT TO THE TERMS OF THAT CERTAIN SECURITIES PURCHASE AGREEMENT, DATED JANUARY 9, 2023, BY AND AMONG THE COMPANY AND THE INVESTORS NAMED THEREIN, IN AN AMOUNT IN EXCESS O

CAPITAL STRUCTURE

Meeting held 2025-04-10.

Combines 2 wordings of this item as funds reported it.

100% fund support · no official result

FOR 100%

The 8 asset managers below cast 100% of the shares they voted on this item FOR (5,157,782 for, 0 against).

FOR: 5,157,782 (100.0%)

Largest asset managers voting on “FOR PURPOSES OF COMPLYING WITH NASDAQ LISTING RULE 5635(D), TO APPROVE THE ISSUANCE OF SHARES OF OUR COMMON ST” at LIFECORE BIOMEDICAL INC., 2024-2025
Asset manager	For	Vote
Legion Partners Asset Management, LLC	4,431,823	For
BlackRock	625,781	For
QUANTITATIVE MASTER SERIES LLC	36,236	For
RBC FUNDS TRUST	29,300	For
Gabelli	13,500	For
Bridge Builder Trust	11,817	For
John Hancock	9,255	For
Advisors' Inner Circle Fund III	70	For

Largest LIFECORE BIOMEDICAL INC. shareholders voting in 2024-2025

Ranked by the number of LIFECORE BIOMEDICAL INC. shares each manager voted on the most widely held ballot item of the 2024-2025 meeting, shown as a share of the 30,898,255 shares outstanding at the time of that meeting.

Top LIFECORE BIOMEDICAL INC. shareholders by shares voted, 2024-2025
#	Asset manager	% of shares outstanding
1	Legion Partners Asset Management, LLC	14.25%
2	Greenhaven Road Investment Management, L.P.	11.70%
3	WYNNEFIELD CAPITAL INC	11.27%
4	22NW, LP	5.73%
5	325 CAPITAL LLC	4.43%
6	Vanguard	4.26%
7	BlackRock	2.38%
8	State Street	0.97%
9	DCF Advisers, LLC	0.93%
10	Rangeley Capital, LLC	0.69%

Reported LIFECORE BIOMEDICAL INC. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

LIFECORE BIOMEDICAL INC. beneficial owners on record for the 2024-2025 proxy season
Holder	% outstanding	Disclosure
Christopher S. Kiper	21.89%	DEF14A
Legion Partners Asset Management, LLC	21.89%	DEF14A
Nelson Obus	17.54%	DEF14A
Wynnefield Capital, Inc.	17.54%	DEF14A
Capital	9.98%	DEF14A
22NW, LP	9.79%	DEF14A
22NW Fund, LP	9.63%	13D
Greenhaven Road Investment Management, L.P.	7.66%	13G
LW Capital Management	6.15%	DEF14A
David Capital Partners, LLC	5.84%	13G

Percentages above are of 30,898,255 shares outstanding, as reported by LIFECORE BIOMEDICAL INC. on its Form 10-Q dated 2024-09-27 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from LIFECORE BIOMEDICAL INC.’s 10-Q dated 2024-09-27. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At LIFECORE BIOMEDICAL INC.'s 3 shareholder meetings in the 2024-2025 proxy season (held 2024-08-15, 2024-11-07 and 2025-04-10), 105 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,070 separate fund positions. Their filings are grouped here into 18 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item of the season, voted at the meeting held 2024-11-07 — To approve a non-binding advisory proposal on the compensation of the Company's named executive… — FOR was 99.3% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: LIFECORE BIOMEDICAL INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2024-11-08.

LIFECORE BIOMEDICAL INC. proxy season coverage: 2024-2025 (this page) · 2025-2026.